Dr Victor Tovar Colunga, AUD | |
6101 N Fresno Street, Suite 102, Fresno, CA 93710 | |
(559) 432-2650 | |
(559) 435-4618 |
Full Name | Dr Victor Tovar Colunga |
---|---|
Gender | Male |
Speciality | Qualified Audiologist |
Experience | 17 Years |
Location | 6101 N Fresno Street, Fresno, California |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1174655278 | NPI | - | NPPES |
P00048503 | Other | RAILROAD MEDICARE |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
231H00000X | Audiologist | AU1523 (California) | Primary |
237600000X | Audiologist-hearing Aid Fitter | HA3371 (California) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Central Calif Ent Medical Group | 6901853316 | 17 |
News Archive
University of North Carolina Lineberger Comprehensive Cancer Center researchers have found that by helping to form clots within tumors, immune cells that flock to a particular type of lung cancer are actually building a foundation for the tumor to spread within the body.
Researchers at RAND found the result of offering rebates for healthy foods can lead to shifts in diets, which could have public policy implications.
A new government proposal would cut reimbursement rates for doctors who accept Medicare by 30 percent in 2012.
A protein activated by certain drugs already approved for treating Type II diabetes may slow or stop the spread of breast tumors.
The National Comprehensive Cancer Network Oncology Research Program and AstraZeneca, a global, science-led biopharmaceutical company, are collaborating to seek proposals for improving care processes for patients with unresectable stage III and stage IV non-small cell lung cancer.
› Verified 4 days ago
Provider Name | Central Calif Ent Medical Group |
---|---|
Provider Type | Part B Supplier - Clinic/group Practice |
Provider Identifiers | NPI Number: 1083673842 PECOS PAC ID: 6901853316 Enrollment ID: O20050406001264 |
News Archive
University of North Carolina Lineberger Comprehensive Cancer Center researchers have found that by helping to form clots within tumors, immune cells that flock to a particular type of lung cancer are actually building a foundation for the tumor to spread within the body.
Researchers at RAND found the result of offering rebates for healthy foods can lead to shifts in diets, which could have public policy implications.
A new government proposal would cut reimbursement rates for doctors who accept Medicare by 30 percent in 2012.
A protein activated by certain drugs already approved for treating Type II diabetes may slow or stop the spread of breast tumors.
The National Comprehensive Cancer Network Oncology Research Program and AstraZeneca, a global, science-led biopharmaceutical company, are collaborating to seek proposals for improving care processes for patients with unresectable stage III and stage IV non-small cell lung cancer.
› Verified 4 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Victor Tovar Colunga, AUD 6101 N Fresno Street, Suite 102, Fresno, CA 93710 Ph: (559) 432-2650 | Dr Victor Tovar Colunga, AUD 6101 N Fresno Street, Suite 102, Fresno, CA 93710 Ph: (559) 432-2650 |
News Archive
University of North Carolina Lineberger Comprehensive Cancer Center researchers have found that by helping to form clots within tumors, immune cells that flock to a particular type of lung cancer are actually building a foundation for the tumor to spread within the body.
Researchers at RAND found the result of offering rebates for healthy foods can lead to shifts in diets, which could have public policy implications.
A new government proposal would cut reimbursement rates for doctors who accept Medicare by 30 percent in 2012.
A protein activated by certain drugs already approved for treating Type II diabetes may slow or stop the spread of breast tumors.
The National Comprehensive Cancer Network Oncology Research Program and AstraZeneca, a global, science-led biopharmaceutical company, are collaborating to seek proposals for improving care processes for patients with unresectable stage III and stage IV non-small cell lung cancer.
› Verified 4 days ago